rs4061073
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_145716.4(SSBP3):c.928-2244T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.275 in 152,136 control chromosomes in the GnomAD database, including 5,903 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.28 ( 5903 hom., cov: 32)
Consequence
SSBP3
NM_145716.4 intron
NM_145716.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.590
Publications
10 publications found
Genes affected
SSBP3 (HGNC:15674): (single stranded DNA binding protein 3) Predicted to enable single-stranded DNA binding activity and transcription coactivator activity. Predicted to be involved in head development and positive regulation of transcription by RNA polymerase II. Predicted to act upstream of or within hematopoietic progenitor cell differentiation. Predicted to be part of protein-containing complex. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.31 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SSBP3 | NM_145716.4 | c.928-2244T>C | intron_variant | Intron 14 of 17 | ENST00000610401.6 | NP_663768.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SSBP3 | ENST00000610401.6 | c.928-2244T>C | intron_variant | Intron 14 of 17 | 5 | NM_145716.4 | ENSP00000479674.2 |
Frequencies
GnomAD3 genomes AF: 0.276 AC: 41900AN: 152018Hom.: 5900 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
41900
AN:
152018
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.275 AC: 41910AN: 152136Hom.: 5903 Cov.: 32 AF XY: 0.269 AC XY: 20042AN XY: 74372 show subpopulations
GnomAD4 genome
AF:
AC:
41910
AN:
152136
Hom.:
Cov.:
32
AF XY:
AC XY:
20042
AN XY:
74372
show subpopulations
African (AFR)
AF:
AC:
10023
AN:
41494
American (AMR)
AF:
AC:
4047
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
AC:
905
AN:
3468
East Asian (EAS)
AF:
AC:
866
AN:
5172
South Asian (SAS)
AF:
AC:
1121
AN:
4826
European-Finnish (FIN)
AF:
AC:
2802
AN:
10590
Middle Eastern (MID)
AF:
AC:
75
AN:
294
European-Non Finnish (NFE)
AF:
AC:
21284
AN:
67976
Other (OTH)
AF:
AC:
518
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1572
3144
4716
6288
7860
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
424
848
1272
1696
2120
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
789
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.